

*Sub C2*

7. (TWICE AMENDED) A peptide compound comprising a sequence of at least 8 consecutive amino acids of a natural hsp70 sequence, the sequence having at least one mutation or modification with respect to the natural hsp70 sequence, and wherein the peptide compound brings about a specific T response.

*Sub C2*

11. (TWICE AMENDED) The peptide compound as claimed in claim 7, further comprising at least one element other than natural amino acids, wherein the element provides at least one of the following functions regarding the peptide compound: chemical protection, physical protection, promotion of absorption by the body, promotion of administration, and promotion of bioavailability.

*Sub C3*

13. (TWICE AMENDED) A vector for expressing the peptide compound as claimed in claim 7, comprising a DNA fragment encoding a peptide fragment of hsp70, wherein the DNA fragment is fused to a promoter that is strong and effective in eukaryotic or in prokaryotic cells or in both eukaryotic and prokaryotic cells.

*B3*  
*mb*  
*el*

14. (TWICE AMENDED) The vector as claimed in claim 13, further comprising at least one selection marker and, optionally, at least one coding sequence for cytokines or lymphokines or for both cytokines and lymphokines.

### REMARKS

Entry and consideration of the amendments to the specification and claims is respectfully requested.

### Claim Objection

In response to the rejection of the claims raised by the Office in item four, Applicants have added the phrase "What is claimed is:" to the specification before the

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)